Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia

[1]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[2]  J. Moyano,et al.  Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. , 2015, European urology.

[3]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[4]  Steven L. Chang,et al.  Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Albanes,et al.  Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage I lung cancers. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Burki.  Cancer survivors continue to smoke. , 2014, The Lancet. Oncology.

[7]  Richard Sylvester,et al.  Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. , 2013, European urology.

[8]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[9]  J. Beyene,et al.  Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. , 2013, European urology.

[10]  Y. Lotan,et al.  Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder , 2013, British Journal of Cancer.

[11]  Tianyuan Xu,et al.  Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models. , 2013, Urology.

[12]  M. Nicolai,et al.  Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Using EORTC Risk Tables , 2012, Urologia Internationalis.

[13]  L. Martínez-Piñeiro,et al.  The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. , 2011, European urology.

[14]  H. Matsuyama,et al.  Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines , 2011, BJU international.

[15]  Duolao Wang,et al.  Do Standardised Prognostic Algorithms Reflect Local Practice? Application of EORTC Risk Tables for Non-Muscle Invasive (pTa/pT1) Bladder Cancer Recurrence and Progression in a Local Cohort , 2011, TheScientificWorldJournal.

[16]  T. H. van der Kwast,et al.  Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. , 2010, European urology.

[17]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[18]  Choal Hee Park,et al.  The Efficacy of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer after Intravesical Bacillus Calmette-Guerin Instillation , 2010, Korean journal of urology.

[19]  L. Martínez-Piñeiro,et al.  Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.

[20]  Y. Mizutani,et al.  Clinical outcome of tumor recurrence for Ta, T1 non‐muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999–2001 report from the Japanese Urological Association , 2009, International journal of urology : official journal of the Japanese Urological Association.

[21]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[22]  Choung-Soo Kim,et al.  Nomograms for Prediction of Disease Recurrence in Patients with Primary Ta, T1 Transitional Cell Carcinoma of the Bladder , 2008, Journal of Korean medical science.

[23]  D. Parkin,et al.  The evolution of the population-based cancer registry , 2006, Nature Reviews Cancer.

[24]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[25]  R. Dunn,et al.  Gender and geographic influence on the racial disparity in bladder cancer mortality in the US. , 2006, Journal of the American College of Surgeons.

[26]  L. Sobin,et al.  Histological Typing of Urinary Bladder Tumours , 1999, International Histological Classification of Tumours.

[27]  V. Brower.  Anti-PD-L1 antibody active in metastatic bladder cancer. , 2015, The Lancet. Oncology.

[28]  D. Lamm,et al.  Re: Behfar Ehdaie, Richard Sylvester, Harry W. Herr. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579-85. , 2014, European urology.

[29]  M. Babjuk,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. , 2013, European urology.

[30]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[31]  International classification of tumours. , 1967, Lancet.